Aspire's sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes after dosing
TxB2 is a biomarker indicating aspirin's effect on platelet aggregation, the clumping of platelets that leads to dangerous blood clots
This rapid inhibition is critical during suspected heart attacks, when clots blocking heart arteries can cause permanent muscle damage
Lab results showed Aspire's product acted approximately twice as fast as the current recommendation for chewed aspirin tablet treatment
These clinical trial results enable a potential regulatory submission for accelerated approval on track for Q3 2025
"A shift to Schedule III could unlock a $30+ billion market, eliminate crippling 280E tax burdens, unleash institutional investment, and set the stage for explosive industry-wide growth."
Read More- Industry veteran brings extensive senior level leadership and expertise in biologics development, strategic partnerships, mergers and acquisitions across biotech and large pharma organizations
- Operating experience to significantly enhance development program of CID-103 (anti-CD38 mAb)
Read More
After the EPA dismissed employees who publicly criticized its leadership, attention is turning to the Drug Enforcement Administration's Diversion Control Division, long accused of obstructing FDA-approved cannabis research. With DEA officials Matthew Strait and Thomas Prevoznik retired and attorney Aarathi Haig facing ethical questions, patient advocates warn that new DEA Administrator Terry Cole may soon be forced to take similar disciplinary action against insiders who blocked MMJ BioPharma Cultivation's clinical trials for Huntington's disease and Multiple Sclerosis.
Read More
In the first half of 2025, 88% of boards required ROI projections for all new IT projects, and more than half of U.S. hospitals (52%) delayed or canceled initiatives with ROI timelines longer than 24 months.
Read More
Facial plastic surgeons at Becker Plastic Surgery explain how the deep plane facelift differs from traditional techniques, focusing on repositioning deeper tissues to address advanced mid-face and neck aging.
Read MoreCompany to host webcast today at 8.00 a.m. ET
Growing portfolio of RNA delivery clients and programs
Advancing plans for partial spin-off of RNA delivery activities
Continued adjustment of cost structure
Learn How Brello Health's Telehealth GLP-1 Weight Loss Program Combines Semaglutide, Tirzepatide, and Expert Coaching for Safe, Sustainable Results in 2025
Read More
Justice Delayed Is Justice Denied
The retirement of Matthew Strait and Thomas Prevoznik is not closure-it is the beginning of a reckoning with the DEA's culture of obstruction.
"Thomas Prevoznik may have pulled the trigger, but Matthew Strait loaded the gun," said Duane Boise, CEO of MMJ International Holdings. "Now the question is whether Administrator Cole will keep allowing Aarathi Haig to pull the strings, or whether he'll finally restore constitutional accountability. Patients' lives depend on it."
The Seven Year Regulatory Ordeal Blocking Medical Innovation
Read MoreIn vitro findings reveal Telomir-1's dual action: targeting DNA methylation switches and cutting into the Wnt "fuel line" that drives cancer growth.
Read More
NECANN New Jersey attracts over 5,000 industry leaders, features more than 200 exhibitors, and is ranked the 3rd largest B2B cannabis convention in the United States - positioning CBDL for unprecedented growth, revenue opportunities, and investor value.
Read More
Nearly 50 groups, including CatholicVote, are lobbying Trump to keep marijuana Schedule I - but where is that same passion for the patients? While faith leaders focus on fear, the DEA blocks MMJ BioPharma's FDA-approved clinical trials for Huntington's and Multiple Sclerosis, trapping science in an unconstitutional kangaroo court. This fight isn't about recreational weed - it's about whether America will allow DEA to stand between the sick and real medicine.
Read More
